Antiviral combination therapy

This page covers all Antiviral combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Interferon-alpha receptor; HCV RNA-dependent RNA polymerase, Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase, Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase.

Targets

Interferon-alpha receptor; HCV RNA-dependent RNA polymerase · Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase · Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase · Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase · Interferon-alpha receptor; viral RNA-dependent RNA polymerase · HCV RNA-dependent RNA polymerase; interferon-alpha receptor · Interferon alpha receptor; HCV RNA polymerase · Interferon-alpha receptor; HCV RNA polymerase · Interferon-alpha receptor (IFNAR); Hepatitis C virus RNA-dependent RNA polymerase · Interferon-α receptor; viral RNA-dependent RNA polymerase

Marketed (20)

• Peg-IFN + RBV · National Taiwan University Hospital · Virology/Hepatology
  Pegylated interferon alpha and ribavirin work together to inhibit viral replication and enhance immune response against hepatitis C virus.
• pegylated IFN alfa-2b plus ribavirin · National Taiwan University Hospital · Virology/Hepatology
  Pegylated interferon alfa-2b activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.
• pegylated interferon alpha 2a, ribavirin · Kaohsiung Medical University Chung-Ho Memorial Hospital · Virology/Infectious Disease
  Pegylated interferon alpha 2a activates innate immune responses against viral infections, while ribavirin inhibits viral RNA synthesis, together providing antiviral activity primarily against hepatitis C virus.
• Pegylated interferon alfa-2a + Ribavirin · University of California, San Francisco · Virology/Infectious Disease
  Pegylated interferon alfa-2a activates innate immunity to suppress viral replication, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus.
• C: Peg-interferon alpha-2a & Ribavirin · Kaohsiung Medical University Chung-Ho Memorial Hospital · Virology/Hepatology
  Pegylated interferon alpha-2a activates innate immune responses against hepatitis C virus, while ribavirin inhibits viral replication through multiple mechanisms including nucleotide synthesis disruption.
• E: Peg-interferon alpha-2a & Ribavirin · Kaohsiung Medical University Chung-Ho Memorial Hospital · Virology/Infectious Disease
  Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication.
• F: Peg-interferon alpha-2a & Ribavirin · Kaohsiung Medical University Chung-Ho Memorial Hospital · Virology/Hepatology
  Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.
• Ribavirin, Peg interferon alfa 2b · Brooke Army Medical Center · Virology/Infectious Disease
  Ribavirin and peginterferon alfa-2b work together to inhibit viral replication and enhance immune response against hepatitis C virus.
• Peg-IFN + LD RBV for 16 weeks · National Taiwan University Hospital · Virology/Hepatology
  Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress viral replication in hepatitis C infection.
• Peg-IFN + WB RBV for 48 weeks · National Taiwan University Hospital · Infectious Disease / Virology
  Pegylated interferon alpha combined with weight-based ribavirin stimulates the immune system to clear hepatitis C virus infection.
• B: Peg-interferon alpha-2a & Ribavirin · Kaohsiung Medical University Chung-Ho Memorial Hospital · Virology/Hepatology
  Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.
• interferon α 2b + ribavirin · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · Virology / Infectious Disease
  Interferon α-2b activates innate immunity and has direct antiviral activity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication.
• Peg interferon + Ribavirin · University of Valencia · Virology/Hepatology
  Pegylated interferon alpha activates innate immunity to suppress viral replication, while ribavirin inhibits viral RNA synthesis and reduces viral load.
• Pegylated interferon and ribavirin · Pacific Health Foundation · Virology/Hepatology
  Pegylated interferon alpha activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication.
• Peg-IFN + LD RBV for 24 weeks · National Taiwan University Hospital · Virology/Hepatology
  Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress hepatitis C virus replication.
• Ganovo+ritonavir+/-Interferon nebulization · The Ninth Hospital of Nanchang · Infectious Disease / Virology
  This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response.
• D: Peg-interferon alpha-2a & Ribavirin · Kaohsiung Medical University Chung-Ho Memorial Hospital · Virology/Infectious Disease
  Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication.
• Quadruple therapy · Sherief Abd-Elsalam · Virology/Hepatology
  Quadruple therapy combines four antiviral agents to simultaneously target multiple stages of viral replication and host factors.
• NAs+IFN-α · Beijing 302 Hospital · Virology/Hepatology
  NAs+IFN-α combines nucleos(t)ide analogues with interferon-alpha to suppress hepatitis B virus replication and enhance antiviral immune response.
• Peg-IFN + WB RBV for 16 weeks · National Taiwan University Hospital · Virology/Hepatology
  Pegylated interferon alpha combined with weight-based ribavirin stimulates the immune system to suppress hepatitis C virus replication.

Phase 3 pipeline (6)

• PEG-Interferon a-2b + Ribavirin · Hepatitis Resource Network · Virology/Hepatology
  PEG-Interferon alfa-2b activates innate immune responses against hepatitis C virus, while ribavirin inhibits viral replication through multiple mechanisms including nucleotide synthesis disruption.
• Peginterferon alfa-2a, Ribavirin, Amantadine · University of Hamburg-Eppendorf · Virology/Infectious Disease
  This triple-drug combination uses peginterferon alfa-2a and ribavirin as antivirals with immunomodulatory effects, plus amantadine as an additional antiviral agent, to suppress viral replication and enhance immune response.
• Peg Interferon alpha2b + Ribavirin · Casa Sollievo della Sofferenza IRCCS · Virology/Hepatology
  Pegylated interferon alpha-2b activates innate immunity to suppress viral replication, while ribavirin inhibits viral RNA synthesis through multiple mechanisms.
• Peg-interferon alpha 2a and ribavin · Hospices Civils de Lyon · Virology/Hepatology
  Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.
• RHB-105 · RedHill Biopharma Limited · Infectious Diseases
  RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19.
• RENESSANS , INTERFERON ALPHA 2b, Ribavirin · MTI Medical Private Limited, Pakistan · Virology/Hepatology
  This combination therapy uses interferon alpha-2b to enhance antiviral immune response and ribavirin to inhibit viral replication, targeting hepatitis C virus.